Drugs / Lirilumab
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03532451 | Mar 2019 → Nov 2020 | urinary bladder cancer | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 1 | NCT03203876 | Jul 2017 → Aug 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02252263 | Dec 2014 → Oct 2017 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01750580 | Dec 2012 → Apr 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03347123 | Mar 2018 → Jan 2021 | cancer | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01714739 | Oct 2012 → Dec 2019 | cancer, familial, with in vitro Radioresistance | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT03341936 | Mar 2018 → Jul 2021 overdue | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02599649 | Mar 2016 → Jan 2019 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02481297 | Jun 2015 → Aug 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02399917 | Apr 2015 → Jul 2018 | acute biphenotypic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01687387 | Oct 2012 → Nov 2016 | acute myeloid leukemia | Innate Pharma | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2017-11-22 | Innate Pharma | Results Innate Pharma provides an update on Lirilumab innate-pharma.com ↗
Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb |
| 2017-02-06 | Innate Pharma | Results Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia innate-pharma.com ↗
The study did not meet its primary efficacy endpoint of leukemia-free survival (LFS). |
| 2016-12-05 | Innate Pharma | Results Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs innate-pharma.com ↗
Early data from the combination of lirilumab with azacytidine show a good safety profile in patients with relapsed acute myeloid leukemia (AML). |
| 2016-11-12 | Innate Pharma | Results Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck innate-pharma.com ↗
Among 29 evaluable patients with SCCHN, the objective response rate (ORR), a secondary endpoint measured by Response Evaluation Criteria In Solid Tumors (RECIST), was 24% (n=7). |
| 2016-11-12 | Bristol-Myers Squibb | Results Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck bms.com ↗
Among 29 evaluable patients with SCCHN, the objective response rate (ORR), a secondary endpoint measured by Response Evaluation Criteria In Solid Tumors (RECIST), was 24% (n=7). |
| 2016-11-08 | Innate Pharma | Results Preliminary Phase 1/2 efficacy data of Lirilumab in combination with Opdivo (Nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck to be presented during SITC meeting innate-pharma.com ↗
Seventeen percent (n=5) of these evaluable patients had deep responses, with reductions in tumor burden greater than 80 percent. |
| 2016-10-09 | Innate Pharma | Results Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress innate-pharma.com ↗
The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy; |
| 2016-10-09 | Bristol-Myers Squibb | Results Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress bms.com ↗
The safety profile of the combination of lirilumab and nivolumab therapy was similar to that of nivolumab monotherapy, with the exception of an increased frequency of low grade infusion-related reactions in patients treated with the lirilumab combinations. |
| 2014-12-09 | Innate Pharma | Results ASH 2014 : Lirilumab enhances Elotuzumab activity in preclinical models innate-pharma.com ↗
The two posters presented show that lirilumab enhances elotuzumab activity in vitro and in vivo and support the rationale for the ongoing Phase I clinical trial combining these agents in MM. |
| 2013-11-14 | Innate Pharma | Results Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH innate-pharma.com ↗
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces that a new set of preclinical data on lirilumab will be presented in a poster at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA: |
| 2012-09-04 | Innate Pharma | Regulatory Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia innate-pharma.com ↗ |
All press releases naming this drug 23 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lirilumab | “evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission” NCT01687387 ↗ |
| Known as | Anti-KIR Antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109500 ↗ |
| Known as | BMS-986015 | “evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission” NCT01687387 ↗ |
| Known as | BMS-986015-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109500 ↗ |
| Known as | IPH2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687387 ↗ |
| Action | Inhibit | “Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109500 ↗3“Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109500 ↗ “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109500 ↗ “Anti-KIR” NCT01714739 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as lirilumab, may interfere with the ability of cancer cells to grow and spread.” NCT02399917 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT01592370 ↗ |
| Target | KIR2DL1 | “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109500 ↗ |
| Target | KIR2DL2 | “Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109500 ↗ |
| Target | KIR2DL3 | “Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109500 ↗ |